About Dynavax Technologies
Dynavax Technologies is a publicly listed company based in Berkeley (United States) founded in 1996, and was acquired by Sanofi in December 2025. It operates as an a biopharmaceutical company focused on developing novel vaccines. It operates on a HealthTech model. Dynavax Technologies has raised $73.9 million across 19 funding rounds from investors including Sanofi, HHS and CDIB Capital Group. The company has 405 employees. Dynavax Technologies has completed 1 acquisition, including Rhein Biotech. Its chief executive is Ryan Spencer. Its website dynavax.com draws about 11 thousand monthly visits. Dynavax Technologies offers products and services including HEPLISAV-B and CpG 1018. Its focus areas include Biotechnology and Vaccines. Its legal entity is Dynavax Technologies Corporation. Its competitors include Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company based in the United States. The company is dedicated to the development and commercialization of novel vaccines aimed at protecting against infectious diseases. Innovative adjuvant technology, such as CpG 1018, is utilized to enhance immune responses. Key products include HEPLISAV-B, a vaccine for hepatitis B prevention. The company operates within the healthcare sector, specifically focusing on biotechnology and vaccine solutions.
- Headquarters Berkeley, United States
- Employees 405
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website dynavax.com
- Social LinkedIn X
- Acquired by Sanofi (Dec 2025)
- Legal Name Dynavax Technologies Corporation
Products & Services of Dynavax Technologies
Dynavax Technologies offers a comprehensive portfolio of products and services, including HEPLISAV-B and CpG 1018.
A vaccine developed for preventing hepatitis B infection.
An adjuvant used to enhance vaccine immune response.
Funding Insights of Dynavax Technologies
Dynavax Technologies has successfully raised a total of $73.9M across 19 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $73.9M
- Total Rounds 19
- First Round $16.5M
(Jul 1999)
- Investors Count 15
Latest 10 of 19 funding rounds of Dynavax Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | – | Post-IPO | – | – | |
| May 2021 | $200M | Post-IPO | – | – | – |
| Feb 2018 | $175M | Debt – Conventional | – | – | |
| Aug 2014 | $425,278 | Grant | – | – | |
| Sep 2013 | $223,390 | Grant | – | – | |
| Jun 2012 | $1.67M | Grant | – | – | |
| Jul 2011 | $589,584 | Grant | – | – | |
| May 2010 | $181,000 | Post-IPO | – | – | – |
| Jan 2010 | $20.07M | Post-IPO | – | – | – |
| Jun 2009 | $1.81M | Grant | – | – |
16 investors in total: 16 institutional.
Investors in Dynavax Technologies
Dynavax Technologies has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Sanofi, HHS and CDIB Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
CRG is recognized as a premier healthcare investment partner. | – | crglp.com | Houston, United States | |
- | – | carecapital.com | - | |
Life Sciences focused VC firm that does early stage investments in the US | – | forwardventures.com | San Diego, United States | |
- | – | healthcap.eu | - | |
- | – | biovedavc.com | - | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
- | – | axiomventures.com | - | |
Biomedical investment financing and active management services. | – | sanderling.com | - |
Investor details for Dynavax Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dynavax Technologies
150 people are tracked at Dynavax Technologies (91 in leadership, 8 in board & advisors, 51 in team); the tracked headcount is 405.
| Name | Role | Group |
|---|---|---|
Ryan Spencer | CEO | Leadership |
Eddie Gray | CEO | Leadership |
Friedhelm Helling | VP, Process Development & Manufacturing Sciences | Leadership |
Robert Janssen | SVP, Clinical Development & Chief Medical Officer | Leadership |
David Novack | President & COO | Leadership |
Andrew Davis | Chief Business Officer | Leadership |
Sheridan Blake Matthews | Senior Director Of Marketing | Leadership |
Leslie dela Cruz | Executive Director, Drug Safety & Pharmacovigilance | Leadership |
Seth Conover | Senior Director, IT Infrastructure & Security | Leadership |
Matthew J Bottomley | Executive Director | Leadership |
Theresa Cassino | Senior Director Project Management | Leadership |
Wendy Komaroff | Executive Director, GCP & GVP Quality And Compliance | Leadership |
Dong Y. | Senior Vice President Research | Leadership |
Duwanda J. Beacham | Director Of Gxp Applications | Leadership |
Kandace Jones | Associate Director Of Compliance | Leadership |
Justin Harano | Associate Director, Fp&a | Leadership |
John Darren Campbell | Senior Director, Immunology & Platform Leader | Leadership |
Rob Zuilkowski | Director, CMC Project Management | Leadership |
Kelly MacDonald | CFO | Leadership |
Manasi Gupte | Associate Director, Gxp Applications | Leadership |
130 more people are available in the full profile.
Complete people profiles for Dynavax Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dynavax Technologies
Dynavax Technologies is a publicly listed company on the NASDAQ with ticker symbol DVAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Feb 2004
- Listed onNASDAQ: DVAX
- Listed entityDynavax Technologies Corporation
- Exchange sectorHealth technology
- ISINUS2681582019
- Share price$15.50 · 2026-02-11
- Market capitalisation$1.82B
- EPS (diluted, trailing year)$-0.38
- Volume (last session)7,106,122
- Analyst consensusStrong buy
Financials of Dynavax Technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $277.2M | $27.3M | $3.9M |
| 2023 | $232.3M | -$6.4M | -$26.8M |
| 2022 | $722.7M | $292.9M | $291.4M |
| 2021 | $437.0M | $72.1M | $140.0M |
| 2020 | $46.5M | -$75.2M | -$65.9M |
Detailed financial statements for Dynavax Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dynavax Technologies
Dynavax Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Rhein Biotech.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic solutions for infectious and inflammatory diseases are developed. | rheinbiotech.com | Dusseldorf, Germany | 1993 | Apr 2006 | •••• |
Complete acquisition details for Dynavax Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Dynavax Technologies
6 dated milestones of Dynavax Technologies across 29 years, from founding to its latest funding, stage changes and deals.
- Founded Dynavax Technologies is founded.
- Funding First funding round of $16.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Rhein Biotech.
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Sanofi.
Competitors of Dynavax Technologies
Dynavax Technologies has 9 listed competitors in our database, 9 of them funded. They include Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Dynavax Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dynavax Technologies
The website of Dynavax Technologies (dynavax.com) receives about 11K visits a month and ranks #2,032,192 among all websites worldwide, #2,764 in Biotechnology and Pharmaceuticals.
- Monthly visits11K
▲ 9.5% vs previous month
- Unique visitors5.4K
per month
- Global rank#2,032,192
among all websites
- Category rank#2,764
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.2
- Average visit1 min 04 sec
- DevicesDesktop 54% · Mobile 46%
Websites whose visitors overlap most with Dynavax Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| merck.com | 100% | 656.8K | #78,842 | View details | |
| sepracor.com | 100% | – | – | View details | |
| roche.com | 100% | 1.3M | #42,219 | View details | |
| astrazeneca.com | 100% | 1.3M | #48,983 | View details | |
| wyeth.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Dynavax Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Dynavax Technologies (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dynavax Technologies
Complete news archive for Dynavax Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dynavax Technologies
Dynavax Technologies was founded in 1996 and raised its 1st funding round 3 years after it was founded.
Dynavax Technologies is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Ryan Spencer is the current CEO of Dynavax Technologies.
Dynavax Technologies is a funded company, having raised a total of $73.9M across 19 funding rounds to date. The company's 1st funding round was a Grant of $1.81M, raised on Jul 1999.
Dynavax Technologies has 405 employees.
Annual revenue of Dynavax Technologies is $277.25M as on Dec 31, 2024.
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company based in the United States. The company is dedicated to the development and commercialization of novel vaccines aimed at protecting against infectious diseases. Innovative adjuvant technology, such as CpG 1018, is utilized to enhance immune responses. Key products include HEPLISAV-B, a vaccine for hepatitis B prevention. The company operates within the healthcare sector, specifically focusing on biotechnology and vaccine solutions.
Dynavax Technologies's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Dynavax Technologies offers HEPLISAV-B and CpG 1018.
Yes, Dynavax Technologies is publicly traded on NASDAQ under the ticker symbol DVAX.
Dynavax Technologies has made 1 acquisition, including Rhein Biotech.
Dynavax Technologies has 16 investors. Key investors include Sanofi, HHS, CDIB Capital Group, Piper Jaffray, and Bain Capital Life Sciences.